Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HyperCVAD for VAD-resistant multiple myeloma

M A Dimopoulos1, D Weber, H Kantarjian

  • 1University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

American Journal of Hematology
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracortical BCI Performance is Robust to Changes in Attentional Load During Dual-Tasking.

bioRxiv : the preprint server for biology·2026
Same author

Expert-Level Detection of Epilepsy Markers in EEG on Short and Long Timescales.

NEJM AI·2025
Same author

Awareness of bone strength in patients with neuromuscular disorders: ERN EURO-NMD clinician survey and European patient survey.

Journal of the neurological sciences·2025
Same author

Building consensus on clinical outcome assessments for BCI devices. A summary of the 10th BCI society meeting 2023 workshop.

Journal of neural engineering·2024
Same author

Fecal Microbiota Transfer in Acute Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation.

Visceral medicine·2024
Same author

Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.

Scientific reports·2023
Same journal

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026
Same journal

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

American journal of hematology·2026
Same journal

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

American journal of hematology·2026
Same journal

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.

American journal of hematology·2026
Same journal

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same journal

Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial.

American journal of hematology·2026
See all related articles

This study found that combining cyclophosphamide and VAD (hyperCVAD) is an effective and safe treatment for advanced multiple myeloma patients resistant to standard therapies. The regimen showed a 40% response rate with low mortality, offering a viable option for difficult-to-treat cases.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Pharmacology

Background:

  • Advanced multiple myeloma often becomes resistant to standard treatments like alkylating agents and VAD.
  • There is a critical need for more effective and safer therapeutic regimens for relapsed or refractory multiple myeloma patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of a combination regimen of cyclophosphamide and VAD (hyperCVAD) in patients with advanced multiple myeloma.
  • To assess treatment outcomes, including response rate, duration of remission, survival, and toxicity, in this patient population.

Main Methods:

  • A cohort of 58 patients with advanced multiple myeloma, resistant to or relapsing after prior therapies, were treated with twice-daily cyclophosphamide (1.8 g/m2) combined with VAD (hyperCVAD).
  • Treatment was administered in an outpatient setting, followed by granulocyte colony-stimulating factor (G-CSF) to support granulocyte recovery.

Related Experiment Videos

  • Key outcome measures included response rate, duration of remission, overall survival, and incidence of adverse events, particularly neutropenia.

    • Main Results:

    • The hyperCVAD regimen achieved a 40% response rate (23 out of 58 patients).
    • The median duration of severe neutropenia (granulocytes < 500/microliter) was 4 days, with a low 2% mortality rate.
    • Median survival for all patients was 15 months, and median remission duration for responders was 8 months.

    Conclusions:

    • The combination of fractionated cyclophosphamide and VAD (hyperCVAD) represents an effective and safe rescue treatment for advanced multiple myeloma patients refractory to standard therapies.
    • Patients with favorable prognostic markers such as low lactate dehydrogenase (LDH), low beta-2 microglobulin (B2M), or primary resistant disease demonstrated significantly longer survival.
    • This regimen offers a valuable therapeutic option for a challenging patient subgroup in multiple myeloma treatment.